Excerpt from AXON's Aug 15 PR... it touts its combo technology with donepezil to advance the SoC by reducing the adverse side effects of donepezil. This is no solution for Alz; it's just trying to make donepezil less bad. (i.e. lipstick on pig)
"Axovant and Qaam Pharmaceuticals (Qaam) have entered into an exclusive license agreement under which Axovant expects to develop and, if successful, commercialize products that combine cholinesterase inhibitors with peripheral muscarinic receptor antagonists including glycopyrrolate, which could mitigate the peripheral side effects of cholinesterase inhibitors. Axovant will initially develop RVT-103, a combination of glycopyrrolate and donepezil. In addition, Axovant expects to develop RVT-104, a combination of glycopyrrolate and high-dose rivastigmine. Axovant believes that the intellectual property portfolio licensed from Qaam as part of this transaction provides a strong exclusivity position in this area."
"This program continues to build on our efforts to deliver comprehensive solutions to patients diagnosed with dementia," said Axovant Chief Development Officer Dr. Lawrence Friedhoff, who led the development of Aricept (donepezil) for the treatment of Alzheimer's disease through its approval in 1996. "We believe this product candidate can limit the peripheral side effects of cholinesterase inhibitors which frequently represent an obstacle for patients to adopt or remain on therapy."
Someone should author a hit piece on AXON revealing the truth about its flawed approach on an ineffective SOC, and post it on MF and SA. Seriously! Would like to see the responses from AF, JF, CR and the rest of the cabal who support this lame company.
